Plasmacytoid urothelial carcinoma of the bladder: a case report by Saad Aldousari et al.
Case report Open Access
Plasmacytoid urothelial carcinoma of the bladder:
a case report
Saad Aldousari1, Kanishka Sircar2 and Wassim Kassouf1*
Address: 1Division of Urology and 2Division of Pathology, McGill University HealthCenter, 1650 Cedar Avenue, Rm L8-315, Montreal,
Quebec, Canada
Email: SA - saad979@hotmail.com; KC - kanishka.circar@muhc.mcgill.ca; WK* - wassim.kassouf@muhc.mcgill.ca
*Corresponding author
Published: 28 April 2009 Received: 14 January 2009
Accepted: 5 February 2009
Cases Journal 2009, 2:6647 doi: 10.1186/1757-1626-2-6647
This article is available from: http://casesjournal.com/casesjournal/article/view/2/4/6647
© 2009 Aldousari et al; licensee Cases Network Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Plasmacytoid bladder cancer is a rare variant of transitional cell carcinoma. A 57-year-old man was
referred to our institution for management of invasive transitional cell carcinoma diagnosed at a
peripheral hospital. His complaints were of vague lower abdominal pain with associated urgency and
frequency requiring oxybutynin. Metastatic workup was negative and was subsequently scheduled for
a radical cystectomy. Routine colonoscopy 3 weeks prior to surgery was negative. Intraoperatively,
he was found to have metastatic urothelial cancer involving the cecum and multiple metastatic
deposits within the mesentery of the small intestines. He underwent a palliative cystectomy with ileal
conduit formation. Final pathology revealed metastatic plasmacytoid variant of urothelial cancer.
Histology and immunohistochemistry were compatible with plasmacytoid variant of urothelial
cancer. Here we present our case of this rare variant of urothelial cancer with a review of its
characteristics.
Introduction
Bladder cancer is the 4th most common malignancy in
males. It most commonly exists as epithelial tumor where
90% of cases are transitional cell carcinoma with a
papillary appearance. In recent decades multiple variants
of this epithelial tumor have been described, the
significance of which lies in the impact it has on prognosis
and approach to management. We describe plasmacytoid
variant of transitional cell carcinoma in a 57-year-old man
who was referred to our institution for further manage-
ment. Less than 30 cases have been described in the
literature, and almost all were invasive and metastatic.
Case Presentation
A 57-year-old French Canadian male presented with gross
hematuria and worsening lower urinary tract symptoms.
He was known for a history of recurrent superficial TCC
refractory to two induction courses of BCG. He had a
35-pack year history of smoking and no family history of
genitourinary malignancy. Cystoscopy revealed abnor-
mally ‘edematous appearing’ mucosa in the posterior
wall of the bladder. Urine sent for cytology was negative.
Metastatic workup including CT chest/abdomen/pelvis
and colonoscopy were negative and was subsequently
scheduled for a radical cystectomy. Exploratory
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laparotomy revealed multiple metastatic lesions involving
the GI tract and mesentery. Frozen sections were sent
which were consistent with metastatic poorly differen-
tiated TCC. Since patient was significantly symptomatic,
he underwent a palliative cystectomy with ileal conduit
diversion. Final pathology revealed muscle-invasive high-
grade urothelial carcinoma of the bladder with plasmacy-
toid features penetrating through the entire bladder wall
and into the serosa (Figure 1). Immunostaining was
positive for cytokeratin, confirming plasmacytoid urothe-
lial carcinoma (Figure 2). The metastatic lesions were also
positive for plasmacytoid features (Figure 3). The patho-
logical stage of urothelial cancer was pT3a, N0, M1. The
patient had an uneventful postoperative recovery. He was
discharged 10 days post operatively. He received post-
operative systemic chemotherapy (gemcitabine/cisplatin);
however, he passed away within 6 months due to rapid
progression of disease.
Discussion
Plasmacytoid urothelial carcinoma is an extremely rare
bladder cancer variant. Sahin et al described the first case in
1991 [1]. Since then there have been 24 cases described in
the literature in the form of case reports or case series [2].
This tumor variant arises from the bladder urothelium as
opposed to metastatic or inflammatory infiltration with
plasma-like cells. Histologically, these cells appear in sheets
or single cells infiltrating the lamina propria andmuscularis
mucosa with a high potential for invasion and metastasis.
Most cases described were high grade and poorly differ-
entiatedwithmetastasis at presentation. Cancer cells display
an eccentric nuclei and poorly identified nucleoli. They have
an eosinophilic cytoplasm and a stroma with a predomi-
nantly myxoid quality. Two reports in the literature
described the presence of cells resembling signet ring cell
carcinoma confirmed by mucin positivity [3, 4]. The
plasmacytoid urothelial carcinoma can coexist with non-
invasive papillary urothelial cancer [5], carcinoma in situ [6,
7], or invasive high grade urothelial carcinoma. One recent
report describes a case of infiltrative plasmacytoid carci-
noma of the bladder in a TURBT specimen which after
cystoprostatectomy demonstrated pure plasmacytoid cells
with no urothelial cancer present [8].
When the histological appearance is highly suspicious for
this variant of urothelial carcinoma, immunohistochem-
istry is a key for making the diagnosis. Looking like plasma
Figure 1.
Urothelial carcinoma with plasmacytoid features on low
power.
Figure 2.
Keratin positive margin of urothelial mucosa with transitional
cell carcinoma.
Figure 3.
Mesenteric nodule with keratin positive immunostaining of
metastatic urothelial transitional cell carcinoma.
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cells, these cells also stain positively for CD-138, a plasma
cell marker. But they also stain positively for epithelial
markers like cytokeratin and epithelial membrane antigen
but not for hemopoietic markers like CD-79a, kappa and
lambda light chain. A recent case report by Shimada et al
was the first to show urothelial carcinoma with a
plasmacytoid variant producing both CA19-9 and bHCG
in the absence of trophoblastic tissue [9].
Treatment of this variant is very difficult owing to the late
presentation with metastases and lack of data on its
response to systemic chemotherapy. Interestingly, Khono
and associates recently reported the first pathological
complete response found at radical cystectomy for
cT4N0M0 plasmacytoid urothelial carcinoma treated
with neoadjuvant chemotherapy (methotrexate, vinblas-
tine, etoposide, and cisplatin) [7].
Conclusion
Plasmacytoid urothelial carcinoma is an extremely rare
variant of bladder cancer and is associated with dismal
prognosis. Due to its aggressive nature, multimodal
therapy should be considered; however, the response to
neoadjuvant chemotherapy needs to be further evaluated.
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